MInimal Residual Disease Adapted Strategy

NCT04934475 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

791

Enrollment

NETWORK

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Isatuximab
PROCEDURE: ASCT

Sponsor

Intergroupe Francophone du Myelome

Collaborators

[object Object]
[object Object]
[object Object]